Elizabeth Atchison, MD, senior fellow, Rush University and Illinois Retina Associates Chicago, is the first-place honoree of the Ophthalmology Times Research Scholar Honoree Program. Below is her abstract:
To identify differences in sustained intraocular pressure (IOP) after intravitreous injections of anti-vascular endothelial growth factor (VEGF) drugs in a real-world population.
Patients seeing an ophthalmic provider who is part of the database
We identified patients who received only a single type of anti-VEGF medication (bevacizumab, aflibercept, or ranibizumab) by injection in their right eyes in the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight). Subgroups included patients with age-related macular degeneration (AMD) only, and patients who had not received an anti-VEGF injection for at least 1 year prior to the study. We also looked at those with more than 12, 18 and 25 injections for each of these 3 medications. Outcomes included change in IOP from baseline, rate of clinically significant IOP increase and rates of glaucoma procedures.
23,873 patients were included in the study with a mean follow up of 681 days. 14,774 (62%) patients received bevacizumab, 4,138 (17%) received aflibercept and 4,961 (21%) received ranibizumab. The average number of injections was 6.9 for the All group, 7.8 for the AMD group, and 6.4 for the New group. By drug, there were an average of 6.1 bevacizumab, 8.9 aflibercept and 7.8 ranibizumab injections over the course of the study.
All agents in all groups showed a decrease in IOP from baseline ranging from zero to 0.52 mmHg (Figure 1). A sustained rise of at least 6 mmHg to an IOP over 21 mmHg occurred at a rate of 2.17%, 2.54% and 3.05% for aflibercept, ranibizumab and bevacizumab respectively (Figure 2). With increasing number of injections this proportion increased for the bevacizumab group only to a maximum of 9.5% for those with 25+ injections (Figure 2). No similar increase was noted with the other drugs.